5 FDA Updates in Psychiatry from the First Half of 2025

The first half of 2025 has brought several important US Food and Drug Administration (FDA) updates in psychiatry, ranging from new drug approvals and label expansions to promising trial data. These developments offer fresh treatment options and improved care strategies for conditions such as depression, schizophrenia, bipolar disorder, ADHD, and opioid use disorder (OUD).